



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

October 7, 2024

Daniel de Boer  
Chief Executive Officer  
ProQR Therapeutics N.V.  
2333 CK Leiden  
The Netherlands

**Re: ProQR Therapeutics N.V.**  
**Registration Statement on Form F-3**  
**Filed September 30, 2024**  
**File No. 333-282419**

Dear Daniel de Boer:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Jessica Dickerson at 202-551-8013 with any questions.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences

cc: Mitchell S. Bloom, Esq.